Pim激酶作为早期类风湿关节炎的治疗靶点
本研究探讨Pim-1及其家族成员作为早期类风湿关节炎(RA)治疗靶点的潜力。流式细胞术检测外周血CD4+ T细胞PIM1转录本可作为Pim-1活性的生物标志物,早期RA患者显著高于其他疾病患者。Pim激酶抑制剂可抑制早期RA CD4+ T细胞活化和增殖,减少干扰素-γ和白细胞介素-17产生,扩增调节性T细胞,并在胶原诱导性关节炎小鼠中减轻关节炎进展和软骨破坏。
要点
- 早期RA患者外周血CD4+ T细胞PIM1转录本比例显著高于其他疾病患者。
- Pim激酶抑制剂可抑制早期RA CD4+ T细胞活化增殖并减少促炎细胞因子。
- Pim抑制剂在胶原诱导性关节炎小鼠中减轻关节炎进展和软骨破坏。
核心结论
- Pim激酶是早期RA可识别亚组的潜在治疗靶点,应考虑将Pim抑制剂重定位用于该病。
研究设计与样本
- 研究采用流式细胞术检测早期关节炎患者外周血单核细胞PIM1转录本,并用多重免疫荧光测定滑膜蛋白表达。
- 研究对未治疗RA患者和非RA疾病对照的滑膜组织及新鲜分离CD4+ T细胞进行功能实验,并在胶原诱导性关节炎(CIA)小鼠中评估Pim抑制的影响。
主要发现
- 早期RA患者外周血CD4+ T细胞中PIM1转录本阳性百分比显著高于其他疾病患者。
- 早期RA患者滑膜CD4+ T细胞中Pim-1蛋白水平同样上调。
- 体外暴露于Pim激酶抑制剂可抑制T细胞受体刺激的早期RA CD4+ T细胞活化和增殖能力。
- 暴露于Pim抑制剂的细胞中干扰素-γ和白细胞介素-17产生减少,CD25high FoxP3+调节性T细胞比例扩增。
- 给予Pim抑制剂可显著限制CIA小鼠的关节炎进展和软骨破坏。
临床怎么用
- 流式细胞术检测外周血CD4+ T细胞PIM1转录本可作为早期RA患者Pim-1活性的生物标志物。
- Pim抑制剂可能用于治疗经生物标志物识别的早期RA亚组患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: As well as being an established oncoprotein and therapeutic target in cancer, proviral integration site for Moloney murine leukemia virus 1 (Pim-1) is implicated in human autoimmunity. This study was undertaken to investigate Pim-1 and its family members as potential therapeutic targets in early rheumatoid arthritis (RA). METHODS: A flow cytometry assay for PIM1 transcript measurement in peripheral blood mononuclear cells from patients with early arthritis was validated and applied as a biomarker of Pim-1 activity at the cellular level. Synovial protein expression was similarly determined by multiplex immunofluorescence in tissue samples from untreated RA patients and non-RA disease controls. Functional consequences of Pim kinase family manipulation in freshly isolated CD4+ T cells from these individuals were ascertained, along with the impact of Pim inhibition on mice with collagen-induced arthritis (CIA). RESULTS: The percentage of circulating CD4+ T cells positive for PIM1 transcript by flow cytometry proved a faithful surrogate for gene expression and was significantly higher in patients with early RA than in those with other diseases. Pim-1 protein levels were similarly up-regulated in synovial CD4+ T cells from patients with early RA. Ex vivo, exposure of T cell receptor-stimulated early RA CD4+ T cells to Pim kinase inhibitors restrained their activation and proliferative capacity. Diminished production of proinflammatory cytokines (interferon-γ and interleukin-17) and an expanded CD25high FoxP3+ Treg cell fraction were also observed in exposed versus unexposed cells. Finally, administration of Pim inhibitors robustly limited arthritis progression and cartilage destruction in CIA. CONCLUSION: Our findings indicate that Pim kinases are plausible therapeutic targets in a readily identifiable subgroup of patients with early RA. Repurposing of Pim inhibitors for this disease should be considered.
引用
- Maney NJ, Lemos H, Barron-Millar B, et al. Pim Kinases as Therapeutic Targets in Early Rheumatoid Arthritis. Arthritis Rheumatol. 2021. PMID: 33779060. doi:10.1002/art.41744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。